Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
BMC Bioinformatics
|
May 19, 2019
Improving the power of gene set enrichment analyses
Joanna Roder, Benjamin Linstid, Carlos Oliveira
BMC Medical Informatics and Decision Making
|
July 9, 2021
Explaining multivariate molecular diagnostic tests via Shapley values
Joanna Roder, Laura Maguire, Robert Georgantas, et al.
BMC Bioinformatics
|
June 15, 2019
A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data
Joanna Roder, Carlos Oliveira, Lelia Net, et al.
BMC Bioinformatics
|
May 30, 2019
Robust identification of molecular phenotypes using semi-supervised learning
Heinrich Roder, Carlos Oliveira, Lelia Net, et al.
International Journal of Molecular Sciences
|
February 5, 2020
Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach
Julia Grigorieva, Senait Asmellash, Lelia Net, et al.
Molecules (Basel, Switzerland)
|
February 15, 2022
Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics
Matthew A Koc, Senait Asmellash, Patrick Norman, et al.
Cellular & Molecular Immunology
|
January 25, 2011
In situ mass spectrometry of autoimmune liver diseases
Christopher L Bowlus, Erin H Seeley, Joanna Roder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 2, 2013
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer
Thomas E Stinchcombe, Joanna Roder, Amy H Peterman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 13, 2012
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial
David P Carbone, Keyue Ding, Heinrich Roder, et al.
Clinical Mass Spectrometry (Del Mar, Calif.)
|
November 25, 2021
A proposal for score assignment to characterize biological processes from mass spectral analysis of serum
Joanna Roder, Lelia Net, Carlos Oliveira, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
BMC Bioinformatics
|
May 19, 2019
Improving the power of gene set enrichment analyses
Joanna Roder, Benjamin Linstid, Carlos Oliveira
BMC Medical Informatics and Decision Making
|
July 9, 2021
Explaining multivariate molecular diagnostic tests via Shapley values
Joanna Roder, Laura Maguire, Robert Georgantas, et al.
BMC Bioinformatics
|
June 15, 2019
A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data
Joanna Roder, Carlos Oliveira, Lelia Net, et al.
BMC Bioinformatics
|
May 30, 2019
Robust identification of molecular phenotypes using semi-supervised learning
Heinrich Roder, Carlos Oliveira, Lelia Net, et al.
International Journal of Molecular Sciences
|
February 5, 2020
Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach
Julia Grigorieva, Senait Asmellash, Lelia Net, et al.
Molecules (Basel, Switzerland)
|
February 15, 2022
Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics
Matthew A Koc, Senait Asmellash, Patrick Norman, et al.
Cellular & Molecular Immunology
|
January 25, 2011
In situ mass spectrometry of autoimmune liver diseases
Christopher L Bowlus, Erin H Seeley, Joanna Roder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 2, 2013
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer
Thomas E Stinchcombe, Joanna Roder, Amy H Peterman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 13, 2012
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial
David P Carbone, Keyue Ding, Heinrich Roder, et al.
Clinical Mass Spectrometry (Del Mar, Calif.)
|
November 25, 2021
A proposal for score assignment to characterize biological processes from mass spectral analysis of serum
Joanna Roder, Lelia Net, Carlos Oliveira, et al.
Page
of 3